Drug Profile
LambdaMab - HaemaLogiX
Alternative Names: IST-1458; LambdaMab; MDX-1458Latest Information Update: 22 Nov 2022
Price :
$50
*
At a glance
- Originator Immune System Therapeutics; Medarex
- Developer HaemaLogiX
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyloid light-chain amyloidosis; Multiple myeloma
- Discontinued POEMS syndrome
Most Recent Events
- 22 Nov 2022 Preclinical development is still ongoing for Multiple myeloma in Australia (Parenteral) (HaemaLogiX pipeline, November 2022)
- 22 Nov 2022 Discontinued - Preclinical for POEMS syndrome in Australia (Parenteral) (HaemaLogiX pipeline, November 2022)
- 17 Oct 2022 Preclinical trials in Amyloid light-chain amyloidosis in Australia (Parenteral) (HaemaLogiX pipeline, October 2022)